Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01345006 · ClinicalTrials.gov registry record · Phase 1
Sub-retinal Transplantation of hESC Derived RPE(MA09-hRPE)Cells in Patients With Stargardt's Macular Dystrophy
A Phase 1 study, sponsored by Astellas Institute for Regenerative Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT01345006 is a Phase 1 study that has completed, run by Astellas Institute for Regenerative Medicine. The registered enrollment target is 13 participants.
The verdict
NCT01345006, a Phase 1 study, has completed, sponsored by Astellas Institute for Regenerative Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
This is a safety and tolerability trial to evaluate the effect of subretinal injection of human embryonic stem cell derived retinal pigment epithelium cells in patients with Stargardt's Macular Dystrophy (SMD).
Interventions
- BIOLOGICAL MA09-hRPE
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2011-06-16 |
| Est. Completion | 2015-08-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01345006
The ClinicalTrials.gov registry entry for NCT01345006 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Institute for Regenerative Medicine, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MA09-hRPE is the first listed.
NCT01345006 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01345006 about?
NCT01345006 is a clinical study titled "Sub-retinal Transplantation of hESC Derived RPE(MA09-hRPE)Cells in Patients With Stargardt's Macular Dystrophy". This is a safety and tolerability trial to evaluate the effect of subretinal injection of human embryonic stem cell derived retinal pigment epithelium cells in patients with Stargardt's Macular Dystrophy (SMD).
What is the current status of trial NCT01345006?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2011-06-16. Estimated completion is 2015-08-10.
What interventions are being tested in trial NCT01345006?
The interventions under investigation include: MA09-hRPE (BIOLOGICAL).
Who is sponsoring clinical trial NCT01345006?
This trial is sponsored by Astellas Institute for Regenerative Medicine, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.